Ipamorelin vs Trevogrumab
Head-to-head comparison of Ipamorelin and Trevogrumab for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Ipamorelin | Trevogrumab |
|---|---|---|
| Category | Growth Hormone Secretagogue | Muscle Growth / Monoclonal Antibody |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. | Trevogrumab is an IgG4 monoclonal antibody that binds mature myostatin with high affinity and specificity, preventing it from engaging activin type IIB receptors (ActRIIB) on skeletal muscle cells. |
| Evidence Rating | D — Preclinical | C — Phase II-III clinical trials ongoing |
| Clinical Status | Research-only / Not approved for human use | Phase 2-3 clinical trials. Being studied in TOPAZ program for inclusion body myositis (with garetosmab). |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation | Phase 1 data showed generally well-tolerated profile; Potential for immunogenicity (anti-drug antibodies) |
Overview
Ipamorelin and Trevogrumab are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
Ipamorelin 5mg
5mg
Trevogrumab — Mechanism & Evidence
Trevogrumab (REGN1033) is a fully human monoclonal antibody that specifically binds and neutralizes myostatin (GDF-8), developed by Regeneron Pharmaceuticals. It is being studied in combination with other agents for sarcopenia (age-related muscle loss) and muscle wasting conditions. Trevogrumab represents the pharmaceutical industry approach to myostatin inhibition, offering high target specificity and extended half-life compared to peptide-based approaches. It is being studied in combination with garetosmab (anti-activin A antibody) in the TOPAZ program for inclusion body myositis.
Key claims: Increases lean muscle mass; Treats inclusion body myositis; Highly specific myostatin inhibition.
Shared Research Applications
These peptides target different research areas. Ipamorelin focuses on Anti-Aging, Body Composition, Sleep, while Trevogrumab targets Muscle Wasting, Sarcopenia, Myostatin Inhibition.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation GH-related effects: joint discomfort, mild water retention (1-3 lbs), transient blood glucose elevation in 5-25% of users, usually resolving within 2-4 weeks
Trevogrumab: Phase 1 data showed generally well-tolerated profile Potential for immunogenicity (anti-drug antibodies) Long-term effects of chronic myostatin neutralization are unknown
Shop Research Peptides
Ipamorelin 5mg
5mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.